Compare
United Therapeutics Corp vs Royalty Pharma plc vs Jazz Pharmaceuticals plc vs Sarepta Therapeutics, Inc.
| Latest fiscal year | United Therapeutics Corp UTHR | Royalty Pharma plc RPRX | Jazz Pharmaceuticals plc JAZZ | Sarepta Therapeutics, Inc. SRPT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $3.18B | $2.38B | $4.27B | $2.20B |
| Revenue growth (YoY) | +10.6% | +5.1% | +4.9% | +15.6% |
| Gross margin | 87.9% (computed) | n/a | n/a | n/a |
| Operating margin | 46.9% | 65.6% | -10.1% | -31.8% |
| Net margin | 41.9% | 32.4% | -8.3% | -32.5% |
| Net income | $1.33B | $770.95M | -$356.15M | -$713.41M |
| EPS (Diluted) | $27.86 | $1.78 | -$5.84 | -$7.13 |
| Operating cash flow | $1.56B | $2.49B | $1.36B | -$205.48M |
| Free cash flow | $1.04B | n/a | $1.30B | -$307.45M |
| Cash & equivalents | $1.56B | $618.70M | $1.39B | $801.28M |
| Total assets | $7.88B | $19.62B | $11.66B | $3.35B |
| Total liabilities | $783.80M | $9.91B | n/a | $2.21B |
| Shareholders' equity | $7.10B | $9.71B | $4.32B | $1.14B |
| Return on year-end equity | 18.8% | 7.9% | -8.2% | -62.5% |
| Shares outstanding | 43.64M | n/a | 61.44M | 104.96M |
Revenue, most recent five fiscal years
| Fiscal year | United Therapeutics Corp | Royalty Pharma plc | Jazz Pharmaceuticals plc | Sarepta Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $3.18B Ended 2025-12-31 | $2.38B Ended 2025-12-31 | $4.27B Ended 2025-12-31 | $2.20B Ended 2025-12-31 |
| 1 year earlier | $2.88B Ended 2024-12-31 | $2.26B Ended 2024-12-31 | $4.07B Ended 2024-12-31 | $1.90B Ended 2024-12-31 |
| 2 years earlier | $2.33B Ended 2023-12-31 | $2.35B Ended 2023-12-31 | $3.83B Ended 2023-12-31 | $1.24B Ended 2023-12-31 |
| 3 years earlier | $1.94B Ended 2022-12-31 | $2.24B Ended 2022-12-31 | $3.66B Ended 2022-12-31 | $933.01M Ended 2022-12-31 |
| 4 years earlier | $1.69B Ended 2021-12-31 | $2.29B Ended 2021-12-31 | $3.09B Ended 2021-12-31 | $701.89M Ended 2021-12-31 |